FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
X

Find Oncology Drugs in Phase I Clinical Development in UNITED KINGDOM

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NG-641

            Therapeutic Area: Oncology

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 05, 2020

            Details:

            This is the first time that a tumor-specific virus containing four different therapeutic transgenes has been administered to cancer patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MTL-CEBPA,Pembrolizumab

            Therapeutic Area: Oncology

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 03, 2020

            Details:

            The study is designed to assess the safety, tolerability, pharmacology and clinical activity of MTL-CEBPA in combination with pembrolizumab in these patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Navicixizumab

            Therapeutic Area: Oncology

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Oncologie

            Deal Size: $306.0 million Upfront Cash: $4.0 million

            Deal Type: Licensing Agreement January 13, 2020

            Details:

            Under the terms and conditions of the agreement, Oncologie receives exclusive global license to develop and commercialize navicixizumab.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MRx0518,Pembrolizumab

            Therapeutic Area: Oncology

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 06, 2020

            Details:

            The study is the second opened as part of a strategic collaboration to evaluate 4D's Live Biotherapeutic oncology pipeline across a range of cancer settings.